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Objective: Reconstruction of critical bone defects remains a major orthopae-
dic clinical challenge because of poor bone regeneration, especially angio-
genesis. Implant failure of critical bone defect is often due to avascular
necrosis. A satisfactory vascularisation is a prerequisite for the survival and
integration of new tissue, with existing host tissue. Genetic modification of
biological scaffolds to enhance angiogenesis is one of the effective methods
for bone regeneration. Present work investigates angiogenesis by in vivo
multiphoton microscopy during bone-formation in murine calvarial critical
bone defect, repaired by a genetically modified 3D-printed PLGA/nHAp
scaffold.
Methods: In this study, we attempt to design lentivirus-mediated genetic modi-
fication of three-dimensional porous PLGA/nHAp scaffolds, which can deliver a
recombinant lentivirus carrying the cytokine gene-pdgfb. Lentivirus can be
time-released from the scaffold via a surface of lyophilisation immobilised
strategy. After implanting the PLGA/nHAp scaffolds, modified with lentivirus,
to the critical-sized calvarial bone defect model, we studied how the geneti-
cally modified 3D scaffolds affect the angiogenesis and bone formation by multi-
photon microscopy, RT-qPCR, microCT, and histomorphological methods,
respectively.
Results: We constructed vectors needing to be tested and produced lentiviral
vector particles by using 293FT cells. We successfully fabricated the 3D porous
PLGA/nHAp scaffold to fit the circular bone defect. The in vitro coating,
release, titre, and bioactivity of the lentivirus with the scaffold were tested.
Based on what we did, the lentivirus could be loaded onto the PLGA/nHAp scaf-
fold and survive. The modified scaffolds could continuously release bioactive
LV-pdgfb particles for up to 5 days in vitro. In scaffold implanted critical cal-
varial bone defect mouse model after eight weeks post-implantation, blood
vessel areas (BVA) were 9428944 mm2, 4090680.3 mm2 and none in the
PLGA/nHAp/LV-pdgfb (PHp), PLGA/nHAp (PH), and empty group, respectively.
At each observed time point, BVA in PHp scaffolds was significantly higher than
in PH scaffolds. Additionally, expression of pdgfb and angiogenesis related
genes vWF and VEGFR2 increased correspondingly. MicroCT analysis indicated
that the new bone formation in the PHp group dramatically improved
compared to the other groups, the parameters including bone mineral density
(BMD), the ratio of bone volume to tissue volume (BV/TV), trabecular separa-
tion (Tb.Sp), and trabecular number (Tb.N) were significantly higher than the
other groups.
Conclusion: The results shown in this work demonstrate that a genetically modi-
fied scaffold with pdgfb gene significantly improved angiogenesis and further
enhanced bone regeneration in a mouse critical-size calvarial bone defect model.By using a considered clinically bio-safe viral vector, for example Adeno-associated
virus (AAV) vectors, this strategy and this gene could be a potential therapy for
critical bone defect.
http://dx.doi.org/10.1016/j.jot.2016.06.101137
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Objective: Transcription factor Egr1 (early growth response-1) regulates tendon
differentiation and promotes tendon repair. The function of miRNA that regulate
Egr1 expression remains largely unknown. In our preliminary study, hsa-mir-X
was predicted to target Egr1 by bio-informatic screening. Further investigation
also demonstrated that Egr1 was indeed a direct target of mir-X in tendon derived
stem cells (TDSCs). According to this preliminary data, we hypothesise that anti-
mir-X-3p could promote human TDSC differentiation through regulating the
expression of Egr1.
Methods: The human TDSCs were isolated from a donor’s patellar tendon following
digestion in 2 mg/ml collagenase I. The stemness of TDSCs were confirmed by Oil
red O and Alizarin red staining after adipo-induction and osteo-induction, respec-
tively. To test the function of mir-X in tendon lineage differentiation, we used low-
glucose DMEM containing 10ng/ml TGFb-1 as induction medium in all experiments.
A luciferase assay was used to confirm the binding between mir-X and the pro-
moter reign of Egr1. Collagen formation was measured by Sirus red staining.
Expression of tendon marker genes was verified by qPCR. Western blot was used
to quantify the expression of Egr1 at the protein level. Synthesised mimic of
mir-X and siRNA of Egr1 were both purchased from a commercial company and
transfected into human tendon cells using lipo3000.
Results: 10ng/ml of TGF-b was able to induce the tendon lineage differentiation of
TDSCs. Real-time qPCR results showed increased expression of several tendon
marker genes, including Fmod and Col1a1. Whereas expression of mir-X dramati-
cally decreased with the tenogenic differentiation. The potential binding site be-
tween mir-X and the Egr1 promotor was predicted using TARGET SCAN. The
luciferase assay demonstrated mir-X mimic significantly suppressed luciferase ac-
tivity of the WT reporter. On the contrary, the mutant reporter successfully abol-
ished the suppression effect. The expression level of Egr1 was confirmed in the
protein level by western blot. Furthermore, the inhibitor of mir-X upregulated
the expression of Egr1 at the protein level too. Mir-X mimic transfected TDSCs
exhibited low expression of Fmod and Collagen staining by Sirus red, were totally
blocked. mir-X inhibitor transfection showed the opposite effects. siRNA of Egr1
was co-transfected with a mimic and inhibitor of mir-X. The qPCR and Sirus red
staining showed the inhibitory effects of mir-X on Egr1 expression were partially
abolished.
Conclusion: Taken together, mir-X could inhibit TDSCs’ tenogenic differentiation
by directly suppressing the expression of Egr1. mir-X inhibitors may be developed
as a potential therapeutic agent for promoting tendon repair.
http://dx.doi.org/10.1016/j.jot.2016.06.102
